Article
Gammahydroxybutyrate: An overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent

https://doi.org/10.1016/0149-7634(94)90031-0Get rights and content

Abstract

Gamma-hydroxybutyrate (GHB) is a catabolite in brain of γ-aminobutyrate (GABA) and is also found in nonneuronal tissues. It is present in the brain at about one thousandth of the concentration of its parent compound. High affinity and specific uptake, and energy dependent transport systems for GHB have been described in brain in addition to a class of high affinity binding sites, functional at a rather unphysiologically low pH.

Administration of large doses of GHB to animals and man leads to sedation, and at the highest doses, anaesthesia. These effects are prominent when GHB brain levels are over one hundred-fold the endogenous levels. In some animals, GHB administration also induces an electroencephalographic and behavioural changes resembling that of human petit mal epilepsy. GHB has been used in man as an anaesthetic adjuvant. GHB lowers cerebral energy requirements and may play a neuroprotective role. Administered GHB profoundly effects the cerebral dopaminergic system by a mechanism which remains to be unravelled. GHB has been tested with success on alcoholic patients where it attenuates the withdrawal syndrome. It is indicated here that in this situation, it may owe its effect by acting as a pro-drug of the neurotransmitter GABA into which it can be transformed. As administration of GHB, a GABAB receptor agonist and a natural opioid peptide all elicit similar abnormal EEG phenomena, it may be suggested that they are acting via a common pathway. The petit mal epileptic effects of GHB might be ascribed to its direct, or indirect agonist properties after transformation to a pool of GABA at the GABAB receptor or via interactions at its own binding sites linked to a similar series of biochemical events. Some antivonvulsant drugs, the opiate antagonist naloxone and a synthetic structural GHB analogue antagonise certain behavioural effects of GHB administration. It is postulated that GHB exerts some of its effects via transformation to GABA pools, and that substances which inhibit this process antagonise its effects by blocking GABA formation. GHB has been proposed as a neurotransmitter, although straightforward evidence for this role is lacking. Evidence for and against GHB, as a neurotransmitter, is reviewed here together with a discussion of its potential as a therapeutically useful drug.

References (214)

  • G.J. Cardinale et al.

    Morphine and codeine are endogenous componants of human cerebrospinal fluid

    Life Sci.

    (1987)
  • A. Chapman et al.

    Mechanism of anticonvulsant action of valproate

    Prog. Neurobiol.

    (1982)
  • A.V. Christensen et al.

    GABA-Dopamine/neuroleptic interaction after systemic administration

    Brain Res. Bull.

    (1980)
  • B.R. Cooper et al.

    Neuroleptic-like effects of ethanolamine-O-sulphate in the rat

    Brain Res. Bull.

    (1980)
  • G. Crosby et al.

    Naloxone pretreatment alters the local cerebral metabolic effect of γ-hydroxybutyrate in rats

    Brain Res.

    (1983)
  • M.L. De Ceballos et al.

    Acute and repeated administration of sulpiride alters met- and leu-enkaphalin content of rat brain

    Neurosci. Lett.

    (1986)
  • F.V. DeFeudis

    Effects of psychoactive agents on GABA binding processes

    Neurochem. Internat.

    (1983)
  • A. Depaulis et al.

    Effects of gamma-hydroxybutyrate and gamma-butyrolactone derivatives on spontaneous generalized nonconvulsive seizures in the rat

    Neuropharmacol.

    (1988)
  • M. Diana et al.

    Low doses of γ-hydroxybutyric acid stimulate the firing rate of dopaminergic neurons in unanesthetized rats

    Brain Res.

    (1991)
  • S.J. East et al.

    NMDA receptor activation in rat hippocampus induces cyclic GMP formation through the l-arginine-nitric oxide pathway

    Neurosci. Lett.

    (1991)
  • R.G. Fariello et al.

    The THIP-induced model of bilateral synchronous spike and wave in rodents

    Neuropharmacology

    (1987)
  • J.A. Ferrendelli et al.

    Relationships between seizure activity and cyclic nucleotide levels in brain

    Brain Res.

    (1980)
  • W.N. Fishbein et al.

    Purification and properties of an enzyme in human blood and rat liver microsomes catalising the formation and hydrolysis of γ-lactones. II. Metal ion effects, kinetics and equilibria

    J. Biol. Chem.

    (1966)
  • F. Foote et al.

    Proconvulsant effect of morphine on seizures induced by pentylenetetrazole in the rat

    Eur. J. Pharmacol.

    (1984)
  • J. Garthwaite et al.

    NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices

    Eur. J. Pharmacol.

    (1989)
  • G.L. Gessa et al.

    Selective increase of brain dopamine induced by gamma-hydroxybutyrate

    Life Sci.

    (1966)
  • P. Gloor et al.

    Generalized epilepsy: Some of its cellular mechanisms differ from those of focal epilepsy

    Trends Neurosci.

    (1988)
  • M. Godschalk et al.

    Antagonism of gamma-hydroxybutyrate-induced hypersynchroization in the ECoG of the rat by anti-petit mal drugs

    Neurosci. Lett.

    (1976)
  • M. Godschalk et al.

    Slow wave sleep and a state resembling absence epilepsy induced in the rat by γ-hydroxybutyrate

    Eur. J. Pharmacol.

    (1977)
  • P.L. Gray et al.

    Evidence for GABA tolerance in barbiturate-dependent and withdrawen mice

    Neuropharmacol.

    (1985)
  • N.C. Harris et al.

    The effects of gamma-hydroxybutyrate on the membrane properties of guinea-pig pars compacta neurones in the substantia nigra in vitro

    Neuroscience

    (1989)
  • N. Haykal-Coates et al.

    Pargyline and γ-butyrolactone enhance tyrosine hydroxylase immunostaining of nigrostriatal axons

    Brain Res.

    (1991)
  • V. Hechler et al.

    Selective distribution of γ-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography

    Brain Res.

    (1992)
  • V. Hechler et al.

    Trans-γ-hydroxycrontonic acid binding sites in brain: evidence for a subpopulation of γ-hydroxybutyrate sites

    Neurosci. Lett.

    (1990)
  • E. Hösli et al.

    Binding sites for {3H}γ-hydroxybutyrate on cultured neurones of rat cerebellum and spinal cord

    Neurosci. Lett.

    (1983)
  • L. Hösli et al.

    Action of γ-hydroxybuytyrate and GABA on neurones of cultured rat central nervous system

    Neurosci. Lett.

    (1983)
  • G. Karlsson et al.

    GABAB receptors in various in vitro and in vivo models of epilepsy: A study with the GABAB receptor blocker CGP 35348

    Neurosci.

    (1992)
  • E. Kaufman et al.

    Pyretic action of low doses of γ-hydroxybutyrate in rats

    Biochem. Pharmacol.

    (1990)
  • R.G. Knowles et al.

    Nitric oxide as a signal in blood vessels

    Trends Pharmacol. Sci.

    (1992)
  • N.W. Kowall et al.

    Patterns of cell loss in Huntingdon's disease

    Trends Neurosci.

    (1987)
  • M. Aldegunde et al.

    Naloxone treatment alters the inhibitory effect of gamma-hydroxyybutyric acid on lutenizing hormone secretion in male rats

    Neuroendocrinol. Lett.

    (1990)
  • N.E. Anden et al.

    Effects of drugs influencing monoamine mechanisms on the increase in brain dopamine produced by axotomy or treatment with gamma-hydroxybutyric acid

    Naunyn-Schmiederberg's Arch. Pharmacol.

    (1973)
  • N. Ando et al.

    Regional brain levels of γ-hydroxybuytyrate in Huntingdon's disease

    J. Neurochem.

    (1979)
  • N. Ando et al.

    Inverse relationship between GABA and γ-hydroxybutyrate levels in striatum of rat injected with kainic acid

    J. Neurochem.

    (1979)
  • R. Andrade et al.

    A G protein couples serotonin and GABAB receptors to the same channels in hippocampus

    Science

    (1986)
  • A.A. Artru et al.

    γ-Hydroxybutyrate: Cerebral metabolic, vascular and protective effects

    J. Neurochem.

    (1980)
  • R. Balázs et al.

    The operation of the γ-aminobutyrate bypath of the tricarboxylic acid cycle in brain tissue in vitro

    Biochem. J.

    (1970)
  • A. Bartolini et al.

    Investigations into baclofen analgesia: Effect of naloxone, bicuculline, atropine, and ergotamine

    Br. J. Pharmacol

    (1981)
  • J. Benavides et al.

    A high affinity, Na+-dependent uptake system for γ-hydroxybutyrate in membrane vesicles prepared from rat brain

    J. Neurochem.

    (1982)
  • R. Bernasconi et al.

    Experimental absence seizures: Potential role of γ-hydroxybutyric acid and GABAB receptors

    J. Neural. Transm.

    (1992)
  • Cited by (151)

    • Study of the electro-oxidation of a recreational drug GHB (gamma hydroxybutyric acid) on a platinum catalyst-type electrode through chronoamperometry and spectro-electrochemistry

      2016, Journal of Electroanalytical Chemistry
      Citation Excerpt :

      Gamma hydroxybutyric acid (GHB, Scheme 1) is a drug catalogued as a central nervous system depressant able to produce effects ranging from euphoria, sedation, easing, bradycardia and respiratory depression [1–3].

    • Baclofen and gamma-hydroxybutyrate differentially altered behavior, EEG activity and sleep in rats

      2015, Neuroscience
      Citation Excerpt :

      Data on the positive effects of sleep promotion are rare. Gamma-hydroxybutyrate (GHB), an endogenous metabolite of gamma-aminobutyric acid (GABA), is found in all regions of the mammalian brain and considered to act as a neuromodulator or neurotransmitter (Cash, 1994; Maitre, 1997). High doses of exogenous GHB induce sedation, anesthesia and sleep (Cash, 1994; Carai et al., 2001).

    • Neurotoxic effects induced by gammahydroxybutyric acid (GHB) in male rats

      2009, International Journal of Neuropsychopharmacology
    View all citing articles on Scopus
    View full text